DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

New look. Same commitment. Decision Resources Group becomes Clarivate. Read more here

DRG Knows Global Market Access

Maximizing revenue requires competing in more countries.

Maximizing access globally requires localized strategies.

  • What is the effectiveness of patient access schemes (PAS) globally?
  • Do recommendations by health technology assessment (HTA) agencies in the EU5 place more weight on clinical evidence or economic models?
  • How is reimbursement in Poland being affected by their healthcare system overhaul?

DRG combines country experts possessing deep industry acumen with extensive data and powerful analytic tools to answer the questions critical to your business.


Ask an Analyst

Empowering global access with local knowledge

Our analysts will work with you to scope your business questions in the context you need. Leveraging DRG’s extensive global market access intelligence tools, we will conduct analyses tailored to your business questions, with end deliverables ready for immediate use. From custom data pulls, presentation decks, and online or in-person presentations, we deliver the insights you need – how you need them.

Sifting through the noise takes time, and the essential things you need to know to make good decisions are best pulled out by experts, particularly for your key business needs:



Health Technology Assessment (HTA)

  • Decipher the impact of HTA decisions on the market
  • Explore HTA agency comments and critiques of key clinical and economic methodological strategies
  • Identify analogues/comparators
  • Evaluate HTA/regulatory approval processes and documentation

Pricing & Reimbursement

  • Detect the characteristics of a positive reimbursement decision within a disease/indication:
    • Clinical and economic rationale
    • Restrictions
    • Study design and clinical endpoints
    • Evidence and comparators
  • Examine the pricing and reimbursement landscape of a disease/indication or geography
  • Pinpoint situations where industry can partner with payers

Global Market Access Insights

  • Uncover dynamics between government, private payers, and individuals in mature and emerging markets
  • Map out key stakeholders and cost containment strategies influencing commercial success
  • Probe game-changing trends anticipated to affect the market access environment in individual countries and across regions
  • Isolate commonalities and differences among countries across key metrics

Ask an Analyst